Oct 23
|
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
|
Oct 22
|
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
|
Oct 21
|
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
|
Oct 21
|
TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
|
Oct 20
|
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
|
Oct 20
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
Oct 20
|
IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
|
Oct 19
|
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
|
Oct 18
|
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock
|
Oct 18
|
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
|
Aug 26
|
Ken Fisher’s Top 15 Healthcare Stock Picks
|
Aug 25
|
AstraZeneca sues US over drug pricing laws
|
Aug 25
|
AstraZeneca becomes first international company to file Medicare drug pricing suit
|
Aug 25
|
AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan
|
Aug 25
|
AstraZeneca files lawsuit against U.S. over drug pricing
|
Aug 25
|
AstraZeneca sues US government over drug price reforms
|
Aug 25
|
Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation
|
Aug 25
|
Midday movers: Affirm, Gap, Marvell Technology and more
|
Aug 25
|
AstraZeneca sues US over Medicare drug price negotiation plans
|
Aug 25
|
UPDATE 3-AstraZeneca sues US over Medicare drug price negotiation plans
|